한국형 양극성 장애 약물치료 알고리듬 2018 : 혼재성 양상
- Alternative Title
- Korean Medication Algorithm for Bipolar Disorder 2018 : Mixed Features
- Abstract
- Objectives : The Korean Medication Algorithm for Bipolar Disorder 2018 (KMAP-BP 2018) has been revised again as a result of a consensus of opinions among experts. The mixed episode was changed to mixed features in DSM-5. In this study, we will describe the preference and recommendation of KMAP-BP 2018 for the treatment of mood episodes with mixed features.
Methods : Out of 84 members of the review committee, 61 completed the survey. We analyzed the answers, discussed the data, and held a clinician hearing.
Results : The preferred first-step strategies for mixed features with more manic symptoms were a combination of mood stabilizers (MS), atypical antipsychotics (AAP), and AAP monotherapy. For mixed features with more depressive symptoms, a combination of MS and lamotrigine (LTG), a combination of MS and AAP, and a combination of AAP and LTG were preferred. For mixed features with manic and depressive symptoms, a combination of MS and AAP, and AAP monotherapy were preferred.
Conclusion : For mixed features, a combination of MS and AAP was generally preferred, and lamotrigine was preferred for depressive symptoms. We hope this KMAP-BP 2018 to be helpful for clinicians that treat patients with bipolar disorder in Korea.
- All Author(s)
- W. Kim
; W. M. Bahk
; B. H. Yoon
; D. I. Jon
; J. S. Seo
; J. G. Lee
; J. H. Jeong
; Y. S. Woo
; M. D. Kim
; I. Sohn
; S. H. Shim
; H. R. Song
; K. J. Min
- Issued Date
- 2018
- Type
- Article
- Keyword
- Bipolar disorder; KMAP-BP 2018; Mixed features
- Publisher
- 대한우울조울병학회
Korean Society for Affective Disorders
- ISSN
- 1738-0960
; 2671-4655
- Citation Title
- Mood and Emotion
- Citation Volume
- 16
- Citation Number
- 2
- Citation Start Page
- 69
- Citation End Page
- 76
- Language(ISO)
- kor
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/2479
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.